论文部分内容阅读
目的:对服用缬沙坦联合黄葵胶囊进行治疗的慢性肾小球肾炎蛋白尿患者的作用效果进行评价。方法:选取2015年3月-2016年4月我院进行治疗的87例慢性肾小球肾炎蛋白尿患者,采用随机数字表法分为2组,对照组43例采用服用缬沙坦的方式治疗,观察组44例在对照组治疗的基础上加用黄葵胶囊的方式进行治疗,均治疗2个月。对2组患者治疗前后的24h尿蛋白、SCr、甘油三酯变化程度进行分析。结果:治疗后,观察组与对照组相比,其24h尿蛋白、甘油三酯的含量改善状况较优,两者的差距具有统计学意义,即P<0.05;而治疗后,观察组与对照组相比,其SCr的含量改善状况均较优,两者的差距不具有统计学意义,即P>0.05。结论:缬沙坦联合黄葵胶囊可以明显改善患者体内尿蛋白和甘油三酯含量,降低了肾炎发病状况,值得临床重视。
OBJECTIVE: To evaluate the effect of valsartan combined with Huang Kui capsules in the treatment of chronic glomerulonephritis proteinuria. Methods: Eighty-seven patients with chronic glomerulonephritis albuminuria who were treated in our hospital from March 2015 to April 2016 were randomly divided into two groups according to the random number table method, 43 cases in the control group were treated with valsartan , The observation group 44 cases in the control group based on the use of Huang Kui capsules for treatment, were treated for 2 months. The changes of 24h urinary protein, SCr and triglyceride before and after treatment in 2 groups were analyzed. Results: Compared with the control group, the levels of 24h urine protein and triglyceride in the observation group were better than those in the control group, the difference was statistically significant (P <0.05). After treatment, the observation group and the control group Compared with the control group, the improvement of SCr content was better, and the difference between them was not statistically significant (P> 0.05). Conclusion: Valsartan combined with Huang Kui capsule can significantly improve the urinary protein and triglyceride content in patients, and reduce the incidence of nephritis, deserving clinical attention.